ProCE Banner Activity

TB-PRACTECAL: Efficacy and Safety of Three 24-Wk Oral Regimens for Pulmonary Rifampicin-Resistant TB in Persons With HIV

Slideset Download
Conference Coverage
Bedaquiline, pretomanid, and linezolid with or without clofazimine or moxifloxacin for 24 weeks appeared to be generally safe and effective for the treatment of rifampicin-resistant TB in both people with and without HIV in this randomized, open-label phase II/III trial.

Released: August 04, 2022

Expiration: August 03, 2023

No longer available for credit.


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from

Gilead Sciences, Inc.

ViiV Healthcare


IAS 2021

ProCE Banner